STRATEC REPORTING RESULTS FOR THE FIRST HALF OF 2022 AND CONFIRMS THE FINANCIAL FORECAST (German)

* H1 2022 revenues -11.9% to EUR 137.2 million ^

DGAP-News: STRATEC SE / Keywords: Semi-annual results

STRATEC REPORTS AND CONFIRMED RESULTS FOR THE FIRST HALF OF 2022

FINANCIAL FORECAST

The best jobs of the day

Find the best job offers now and
be notified by e-mail.

08/10/2022 / 06:55

The issuer / publisher is responsible for the content of the application.

————————————————– —————————————

STRATEC REPORTS AND CONFIRMED RESULTS FOR THE FIRST HALF OF 2022

FINANCIAL FORECAST

* H1 2022 revenues -11.9% to EUR 137.2 million (H1 2021: EUR 155.8 million);

Adjusted for the currency -15.2%

* Adjusted EBIT H1 2022 EUR 21.2 million (H1 2021: EUR 34.5 million)

* Adjusted EBIT margin of 15.4% (H1 2021: 22.1%)

* Preparation of serial production of a new system solution for one of the

The market leader is successfully developing

* High level of development activity and a large number of promising negotiations

for new projects

* 2022 forecast confirmation: F / X-adjusted sales increase

Previous year’s level and adjusted EBIT margin of around 16.5% to 18.5%

expected

Birkenfeld, August 10, 2022

STRATEC SE, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,

SDAX) announced today as part of the publication of its semi-annual financial report

H1 | 2022 Explanations on the course of operations and significant events

for the period from January 1, 2022 to June 30, 2022. Results

match with preliminary business data already reported.

KEY NUMBERS 1

in thous. EUR H1 2022 first half 2021 Change Q2 202- Q2 202- Change

rung 2 1 rung

Revenues 137 193 155 765 -11.9% 61 806 83 770 -26.2%

EBITDA 27 841 40 274 ​​-30.9% 9 382 21 434 -56.2%

EBITDA margin 20.3 25.9 -560 bp 15.2 25.6 -1,040

(%) pz

Adjusted EBIT 21 178 34 457 -38.5% 6 141 18 412 -66.6%

Adjusted EBIT margin 15.4 22.1 -670 bp 9.9 22.0 -1 210

(%) pz

Correction 16 679 28 547 -41.6% 4 731 15 400 -69.3%

Group result

Adjusted score 1.38 2.36 -41.5% 0.39 1.27 -69.3%

per share (EUR)

Each result 1.04 2.08 -50.0% 0.12 1.12 -89.3%

Share (EUR)

Adj. = corrected / bp = basis points

1 The revised numbers have been eliminated for comparison

Purchase price allocations from acquisitions and provision for

Expected additional tax payments (including interest payments) adjusted. in

In the past year, an impairment loss was also made

original development project in the Diatron segment.

BUSINESS DEVELOPMENT

The sales of the STRATEC Group in the first half of 2022 amounted to EUR 137.2 million.

EUR (H1 2021: EUR 155.8 million), i.e. 11.9% (currency-adjusted -15.2%)

below the level from the previous year. The drop in sales is mainly because of this

high additional demand last year due to the pandemic (especially in

Q2 2021) according to the possibilities of the molecular diagnostics laboratory

which are not expected to happen in the first half of 2022.

repeated. In addition, they are additionally sharpened against the background

supply chain situation in the last few months

A backlog of deliveries arose. Sales of systems have declined

as a consequence, by 23.6% (after currency adjustment -26.6%) in the first half of 2022, while

in the service parts and consumables industry a decrease by

3.6% (adjusted for the currency effects -7.0%). All in all it was

expected declines in product groups relevant to COVID-19

watch while selling solutions in the field

Immunohematology increased in the double-digit range. Sale of

Development and services could, in spite of being partially, a third

Quarterly deferred revenue recognition, increase by 51.6% (constant currency)

+ 47.1%) can be increased.

The adjusted EBIT margin for the first half of 2022 is

15.4% (H1 2021: 22.1%) and is 670 basis points below the level

from the previous year. In addition to negative economies of scale due to temporary

reduced sales volumes were also a weaker product and

Sales and valuation effects that partially affected earnings

long-term exchange rate hedging transactions. Also located

necessary price adjustments for STRATEC products in connection with

increased input costs, some are still in the implementation phase.

It fell against the background of the lower operating result

consolidated result for the first half of 2022 from EUR 28.5 million to EUR 16.7

million euros. The adjusted earnings per share (undiluted) is EUR 1.38

(1st half of 2021: EUR 2.36).

Data on earnings for the first half of 2022 have been adjusted for comparative purposes

Depreciation on purchase price allocation from acquisitions and on a one-off basis

Provision for expected additional tax payments (including interest)

for the period 2014-2021 (tax costs: EUR 2.3 million; interest costs: EUR 0.2

EUR million) adjusted. The data for the previous year also included a write-down

adapted to its own development project in the Diatron segment. One

Reconciliation of the adjusted data with the data in the consolidated profit and loss account

the reported values ​​can also be published today

Half-year financial statements for the first half of the year | 2022.

FINANCIAL FORECAST

STRATEC expects a backlog that arose in the first half of 2022.

to be able to catch up in the next few months. In addition, due to

Product releases, as well as lower overall

year-on-year comparison, increased dynamics of revenues in the second half of the year

expected in 2022. Against this background and on a current basis

STRATEC confirms orders and order forecasts from customers

their financial guidelines for the financial year 2022. Based on the constants

exchange rates, sales are therefore expected to remain at the previous year’s level.

Adjusted EBIT margin remains unchanged at around 16.5%

Forecast 18.5% (2021: 18.9%).

STRATEC plans to invest in tangible and intangible assets in 2022.

Assets with a total value from 6.0% to 8.0% of planned sales (2021:

7.0%).

PROJECTS AND OTHER REALIZATIONS

In the second quarter of 2022, STRATEC and its partners also contributed

has made significant progress in many development projects

as well as the already young product portfolio with new premieres on the market

expanded. In the Diatron segment, for example the Aquarius 3

launch of a new system for the field of hematology.

Aquarius also offers the end user an easy-to-use solution

exceptional user-friendliness and thus responds to needs

decentralized laboratory settings.

Particular emphasis is now placed on preparation

Serial production of a system solution in the field of digital PCR. this

Introducing the product to the market by a partner, one of the market leaders

in molecular diagnostics, it is inevitable. STRATEC will be

in this project, apart from the analysis system, also to be implemented

produce the complex polymer-based consumables required for testing

and deliver to your partner.

The trend in the IVD industry towards automation solutions

outsourcing of specialized companies is ongoing. This

reflected in the well-stocked development facilities. Additionally

STRATEC is involved in many promising negotiations

Regarding additional development projects.

HR DEVELOPMENT

Against and with a good development path

the related high level of development activity is continued by the STRATEC Group

we are looking for a variety of highly qualified employees. in

STRATEC was able to recruit additional employees in the first half of 2022 and

employed as of June 30, 2022, incl

HR service providers hired employees and interns,

1,429 employees (previous year: 1,400). Compared to the previous year

This corresponds to an increase in the number of employees by 2.1%.

H1 SEMI-ANNUAL FINANCIAL STATEMENTS | 2022

The semi-annual financial statements of STRATEC SE for the 1st half of the year | 2022 are available on the website

companies at www.stratec.com/financial raporty.

CONFERENCE PHONE AND WEBCAST AUDIO

On the occasion of the publication of the final numbers for the top six

Months 2022 takes place today, Wednesday, August 10, 2022 at 2:00 PM (CEST)

conference call in English.

You will receive access data (telephone number, password + individual PIN).

after a short registration at the following link: www.stratec.com/registration

The conference call can also be viewed simultaneously as an audio broadcast over the network

http://www.stratec.com/audiowebcast20220810 (short registration

required) are tracked. Please note that via audio transmission

no questions can be asked. You can also use this link to

Track or download the slide presentation.

ABOUT STRATEC

STRATEC SE (www.stratec.com) plans, develops and produces

fully automatic analytical systems for partners in clinical diagnostics

and natural sciences. In addition, the company offers comprehensive

consumables for diagnostic and medical applications. in

Analytical systems and consumables will be a whole

Value chain from development to design and production

covered by the quality guarantee.

Partners sell systems, software and consumables

around the world as system solutions, usually with their reagents

Laboratories, blood banks and research facilities. STRATEC developed

their products are based on patented technologies.

The company’s shares (ISIN: DE000STRA555) are sold in the market segment

Listed on the Frankfurt Stock Exchange and owned by Prime Standard

SDAX Deutsche Börse selection index.

FOR MORE INFORMATION, CONTACT:

STRATEC SE

Jan Keppeler | Investor relations, sustainable development and corporate communication

Telephone: +49 7082 7916-6515

[email protected]

www.stratec.pl

————————————————– —————————————

08.10.2022 publication of corporate news / financial announcement,

provided by DGAP – EQS Group AG service.

The issuer / publisher is responsible for the content of the application.

DGAP’s distribution services include statutory reporting requirements,

Corporate / financial news and press releases.

Media archive at http://www.dgap.de

————————————————– —————————————

German

Company: STRATEC SE

shopping street 37

75217 Birkenfeld

Germany

Telephone: +49 (0) 7082 7916 0

Fax: +49 (0) 7082 7916 999

E-mail: [email protected]

Internet: www.stratec.com

ISIN: DE000STRA555

WKN: STRA55

Indices: SDAX

Exchanges: Regulated market in Frankfurt (Prime Standard);

Open market in Berlin, Dusseldorf, Hamburg, Hannover,

Munich, Stuttgart, Tradegate Exchange

EQS message ID: 1416619

End of news DGAP news service

————————————————– —————————————

1416619 10/08/2022

°

Leave a Comment